Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY21 results · Oct–Dec 2020

Strides Pharma Science reported revenue from operations of ₹832.02 crore (up 13.6% from Q3 FY20) and net profit of ₹35.16 crore (down 61.9% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	832.02	732.44	+13.6%	793.56	+4.8%
Other income	13.20	12.22	+8.0%	12.87	+2.6%
Total income	845.23	744.66	+13.5%	806.43	+4.8%
Profit before share of associates & JVs and tax	72.85	127.02	−42.6%	98.44	−26.0%
Share of profit/(loss) of associates & JVs	(26.91)	(23.39)		(30.12)
Net profit for the period	35.16	92.33	−61.9%	76.99	−54.3%
Attributable to shareholders of the company	37.85	93.89	−59.7%	80.94	−53.2%
EPS, basic (₹)	4.22	10.48	−59.7%	9.03	−53.3%
Net margin (%)	4.2	12.6		9.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY21	Q3 FY20	YoY	Q2 FY21	QoQ
Revenue from operations	421.08	364.47	+15.5%	384.33	+9.6%
Other income	16.23	17.62	−7.9%	38.54	−57.9%
Total income	437.31	382.09	+14.5%	422.87	+3.4%
Profit before tax	27.36	15.53	+76.2%	19.20	+42.5%
Net profit for the period	20.49	13.65	+50.1%	13.68	+49.8%
EPS, basic (₹)	2.29	1.52	+50.7%	1.53	+49.7%
Net margin (%)	4.9	3.7		3.6

Consolidated

Filed with BSE: 04 Feb 2021, 16:14 IST
Board meeting: 04 Feb 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 04 Feb 2021, 16:14 IST
Board meeting: 04 Feb 2021
Period: 01 Oct 2020 to 31 Dec 2020
Review status: Unaudited
Source: XBRL filing on BSE